Single-dose neonatal gene therapy preserves motor coordination and extends survival of Polg -deficient mice

POLG mutations are the most common single nuclear gene cause of mitochondrial disease. POLG disease spans a spectrum of clinical presentations with variable age of onset and severity. Early-onset disease is often severe and fatal (e.g., Alpers syndrome, myocerebrohepatopathy), while late-onset disease can be relatively mild (e.g., progressive external ophthalmoplegia). POLG disease is incurable, with few symptomatic treatments available, none of which can prevent its progression. Gene replacement therapy has the potential to halt or prevent POLG disease, but its development has been hindered by the large size of the POLG cDNA and the scarcity of suitable mouse models. Here, we developed a bespoke Polg knockout (KO) mouse model by inactivating the Polg locus in parvalbumin-expressing neurons (e.g., Purkinje cells) and fast-twitch skeletal muscle fibers. KO mice developed progressive motor coordination deficits, respiratory chain deficiency in Purkinje cells and skeletal muscle, and died prematurely. We also developed nine AAV-based gene therapy vectors and confirmed their ability to deliver and express the human POLγA protein in different mouse tissues. A single high-dose administration of either of two lead candidates into Polg KO neonates preserved respiratory chain activity in Purkinje cells and skeletal muscle, delayed the onset of motor coordination deficits, and extended lifespan. Thus, our work provides preclinical proof of concept for gene replacement therapy for POLG disease, establishing the feasibility of this approach and laying the foundation for further development in the field.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.17.762423
Primary Topic
Virus-based gene therapy research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Single-dose neonatal gene therapy preserves motor coordination and extends survival of Polg -deficient mice

Metodi Dimitrov Metodiev, Sofia Zanin, Clovis Gaborit, Stephen A. Murray et al.
bioRxiv (Cold Spring Harbor Laboratory)
Virus-based gene therapy research
preprint

Single-dose neonatal gene therapy preserves motor coordination and extends survival of Polg -deficient mice

Metodi Dimitrov Metodiev, Sofia Zanin, Clovis Gaborit, Stephen A. Murray, Benedetta Ruzzenente, Stephen C. Kneeland, Elissa Afram, Stéphanie Moriceau, Arnold Munnich, Maria Teresa Perez-Cartier, Marcelo Simon Sola
preprint en

Abstract

POLG mutations are the most common single nuclear gene cause of mitochondrial disease. POLG disease spans a spectrum of clinical presentations with variable age of onset and severity. Early-onset disease is often severe and fatal (e.g., Alpers syndrome, myocerebrohepatopathy), while late-onset disease can be relatively mild (e.g., progressive external ophthalmoplegia). POLG disease is incurable, with few symptomatic treatments available, none of which can prevent its progression. Gene replacement therapy has the potential to halt or prevent POLG disease, but its development has been hindered by the large size of the POLG cDNA and the scarcity of suitable mouse models. Here, we developed a bespoke Polg knockout (KO) mouse model by inactivating the Polg locus in parvalbumin-expressing neurons (e.g., Purkinje cells) and fast-twitch skeletal muscle fibers. KO mice developed progressive motor coordination deficits, respiratory chain deficiency in Purkinje cells and skeletal muscle, and died prematurely. We also developed nine AAV-based gene therapy vectors and confirmed their ability to deliver and express the human POLγA protein in different mouse tissues. A single high-dose administration of either of two lead candidates into Polg KO neonates preserved respiratory chain activity in Purkinje cells and skeletal muscle, delayed the onset of motor coordination deficits, and extended lifespan. Thus, our work provides preclinical proof of concept for gene replacement therapy for POLG disease, establishing the feasibility of this approach and laying the foundation for further development in the field.

bioRxiv (Cold Spring Harbor Laboratory)
Centre National de la Recherche Scientifique (FR), Inserm (FR), Jackson Laboratory (US), Institut des Maladies Génétiques Imagine (FR)
Institut des maladies génétiques Imagine, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
Good health and well-being
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon